Crossmark

Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation

Crossref DOI link: https://doi.org/10.1186/s12885-018-4802-y

Published Online: 2018-09-12

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fernandes, Gustavo S. http://orcid.org/0000-0003-3426-2167
Girardi, Daniel M.

Bernardes, João Paulo G.

Fonseca, Felipe P.

Fregnani, Eduardo R.
License Information

Text and Data Mining valid from 2018-09-12
More Information

Article History

Received: 30 April 2018

Accepted: 5 September 2018

First Online: 12 September 2018

Ethics approval and consent to participate

: Not applicable.

: Patient written informed consent has been obtained. A copy of the consent form is available for review by the Editor of this journal.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.